论文信息 - Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study. - 字舞流文

Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study.

T. H. Klotz | S. Culine | J. Hainsworth | R. Huddart | G. Scagliotti | B. Hadaschik | J. Carles | B. Mellado | J. Machiels | M. Monga | S. Park | D. Shin | C. Sternberg | K. Decaestecker | A. Santiago-Walker | L. Dirix | W. Schultze‐Seemann | P. O’Donnell | L. Appleman | N. Vogelzang | F. Joly | R. Berardi | N. Houédé | Monica Joshi | A. Necchi | J. García-Donas | Y. Zakharia | A. Font | U. de Giorgi | A. Siefker-Radtke | Y. Loriot | N. Dawson | M. Retz | I. Durán | M. Fleming | S. Tagawa | V. Moreno | G. Facchini | G. Schinzari | S. Srinivas | F. Imkamp | E. Burgess | S. Akapame | S. Rha | A. Fléchon | I. Syndikus | W. Loidl | W. Su | H. Stöger | U. Basso | P. Schatteman | Shian-Shiang Wang | E. Rosenbaum | A. Strauß | D. Gasparro | D. Keizman | Á. Pinto | A. Mosca | O. Parikh | U. Zimmermann | S. Krege | Y. Vano | A. Peer | M. May | M. Joshi | J. Pérez Gracia | S. Zanetta | M. Shkolnik | I. Schnadig | F. Rolland | V. Vladimirov | A. Sella | A. Rezazadeh Kalebasty | R. Delva | A. Hamzaj | A. Rezazadeh | B. Alexeev | I. Bulat | S. Varlamov | C. Cebotaru | V. Matveev | Jae Lyun Lee | K. Tarver | J. Burke | J. Meran | M. Gross Goupil | A. O’Hagan | S. Varlamov | Hyo Jin Lee | A. Izmailov | Eugeniy Kopyltsov | Jesus Gracia Donas | Dephine Borchiellini | Maribel Sáez | Sharad Jain | A. Flechon | H. Stöger | Anne O’Hagan | M. Joshi | A. Rezazadeh Kalebasty | Omi A Parikh | J. L. Pérez Gracia | E. Kopyltsov | D. Borchiellini

[1] T. Powles,et al. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. , 2021, The New England journal of medicine.

[2] A. Ravaud,et al. Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis , 2020, Journal for ImmunoTherapy of Cancer.

[3] T. Powles,et al. 697O A phase III, randomized, open-label study of first-line durvalumab (D) with or without tremelimumab (T) vs standard of care chemotherapy in patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE) , 2020 .

[4] M. Galsky,et al. Infigratinib and treatment response in advanced/unresectable or metastatic urothelial carcinoma in first-line and later-line treatment settings. , 2020 .

[5] S. Pal,et al. Targeted therapies for advanced bladder cancer: new strategies with FGFR inhibitors , 2019, Therapeutic advances in medical oncology.

[6] L. Marandino,et al. Erdafitinib for the treatment of urothelial cancer , 2019, Expert review of anticancer therapy.

[7] R. Huddart,et al. Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. , 2019, The New England journal of medicine.

[8] G. Iyer,et al. Pembrolizumab in the treatment of locally advanced or metastatic urothelial carcinoma: clinical trial evidence and experience , 2019, Therapeutic advances in urology.

[9] J. Hajdenberg,et al. Sacituzumab govitecan (IMMU-132) in patients with previously treated metastatic urothelial cancer (mUC): Results from a phase I/II study. , 2019, Journal of Clinical Oncology.

[10] E. Seront,et al. Immune checkpoint inhibitors as a real hope in advanced urothelial carcinoma , 2018, Future science OA.

[11] P. Hegde,et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial , 2018, The Lancet.

[12] S. Park,et al. Rogaratinib treatment of patients with advanced urothelial carcinomas prescreened for tumor FGFR mRNA expression. , 2018 .

[13] Nicholas J. Vogelzang,et al. Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study , 2017, JAMA oncology.

[14] T. Powles,et al. Updated efficacy and tolerability of durvalumab in locally advanced or metastatic urothelial carcinoma. , 2017 .

[15] C. Murray,et al. Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor , 2017, Molecular Cancer Therapeutics.

[16] E. Plimack,et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. , 2017, The Lancet. Oncology.

[17] Massimo Cristofanilli,et al. Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application , 2016, Oncotarget.

[18] L. Loeb,et al. The influence of subclonal resistance mutations on targeted cancer therapy , 2016, Nature Reviews Clinical Oncology.

[19] P. Bedard,et al. Ocular toxicities of MEK inhibitors and other targeted therapies. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[20] G. Getz,et al. Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition , 2016, Nature Medicine.

[21] L. Mariani,et al. Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[22] N. Schultz,et al. Genomic Characterization of Upper Tract Urothelial Carcinoma. , 2015, European urology.

[23] Razelle Kurzrock,et al. The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing , 2015, Clinical Cancer Research.

[24] W. Pao,et al. Acquired resistance to TKIs in solid tumours: learning from lung cancer , 2014, Nature Reviews Clinical Oncology.

[25] Philippe Bédard,et al. Ocular toxicity of targeted therapies. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26] M Schemper,et al. A note on quantifying follow-up in studies of failure time. , 1996, Controlled clinical trials.